H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results
On May 27, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Tourmaline Bio, Inc. (NASDAQ:TRML) while keeping the price target at $50.
Tourmaline Bio Inc. (TRML)
Market is closed
News
- Displaying 2
BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)
The firm believes that the market’s negative reaction to Phase II data for the company’s drug, Paci, was excessive.
Billionaire Hedge Funds
